Defining Failure of Medical Therapy for Inflammatory Bowel Disease

Area of Science:

• Gastroenterology
• Internal Medicine
• Pharmacology

Background:

• Biologic and small molecule therapies have advanced inflammatory bowel disease (IBD) treatment over 20 years.
• Despite advances, Crohn's disease and ulcerative colitis remain chronic, progressive conditions.
• Failure to optimize or recognize the need for new medical therapy contributes to IBD progression and complications.

Purpose of the Study:

• To define medical therapy failure in inflammatory bowel disease.
• To provide guidance on optimizing current treatments versus switching to new agents.
• To improve management of chronic IBD by addressing treatment efficacy.

Main Methods:

• Literature review of current therapeutic strategies for IBD.
• Analysis of factors contributing to treatment success and failure.
• Synthesis of evidence to guide clinical decision-making in IBD management.

Main Results:

• Prematurely switching therapies can lead to inadequate medication optimization.
• Failing to recognize ongoing inflammation despite optimized treatment can cause disease progression.
• Distinguishing between suboptimal treatment and true therapy failure is essential for effective IBD management.

Conclusions:

• Accurate identification of medical therapy failure is vital for timely intervention in IBD.
• Optimizing current treatment should be considered before abandoning a therapeutic agent.
• This review offers a framework for clinicians to navigate treatment decisions in the evolving landscape of IBD therapy.